Literature DB >> 26290123

Risk factors for venous thromboembolism in women under combined oral contraceptive. The PILl Genetic RIsk Monitoring (PILGRIM) Study.

Pierre Suchon, Fadi Al Frouh, Agathe Henneuse, Manal Ibrahim, Dominique Brunet, Marie-Christine Barthet, Marie-Françoise Aillaud, Geoffroy Venton, Marie-Christine Alessi, David-Alexandre Trégouët, Pierre-Emmanuel Morange1.   

Abstract

Identifying women at risk of venous thromboembolism (VTE) is a major public health issue. The objective of this study was to identify environmental and genetic determinants of VTE risk in a large sample of women under combined oral contraceptives (COC). A total of 968 women who had had one event of VTE during COC use were compared to 874 women under COC but with no personal history of VTE. Clinical data were collected and a systematic thrombophilia screening was performed together with ABO blood group assessment. After adjusting for age, family history, and type and duration of COC use, main environmental determinants of VTE were smoking (odds ratio [OR] =1.65, 95% confidence interval [1.30-2.10]) and a body mass index higher than 35 kg.m⁻² (OR=3.46 [1.81-7.03]). In addition, severe inherited thrombophilia (OR=2.13 [1.32-3.51]) and non-O blood groups (OR=1.98 [1.57-2.49]) were strong genetic risk factors for VTE. Family history poorly predicted thrombophilia as its prevalence was similar in patients with or without first degree family history of VTE (29.3% vs 23.9%, p=0.09). In conclusion, this study confirms the influence of smoking and obesity and shows for the first time the impact of ABO blood group on the risk of VTE in women under COC. It also confirms the inaccuracy of the family history of VTE to detect inherited thrombophilia.

Entities:  

Keywords:  Deep-vein thrombosis; oral contraceptives; thrombophilia

Mesh:

Substances:

Year:  2015        PMID: 26290123     DOI: 10.1160/TH15-01-0045

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  A systematic review of cost-effectiveness analysis of screening interventions for assessing the risk of venous thromboembolism in women considering combined oral contraceptives.

Authors:  Zanfina Ademi; C Simone Sutherland; Joris Van Stiphout; Jöelle Michaud; Goranka Tanackovic; Matthias Schwenkglenks
Journal:  J Thromb Thrombolysis       Date:  2017-11       Impact factor: 2.300

2.  Interaction of a genetic risk score with physical activity, physical inactivity, and body mass index in relation to venous thromboembolism risk.

Authors:  Jihye Kim; Peter Kraft; Kaitlin A Hagan; Laura B Harrington; Sara Lindstroem; Christopher Kabrhel
Journal:  Genet Epidemiol       Date:  2018-03-08       Impact factor: 2.135

3.  First venous thromboembolism and hormonal contraceptives in young French women.

Authors:  Justine Hugon-Rodin; Marie-Hélène Horellou; Jacqueline Conard; Claire Flaujac; Anne Gompel; Geneviève Plu-Bureau
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

4.  Risk prediction of developing venous thrombosis in combined oral contraceptive users.

Authors:  Aaron McDaid; Emmanuelle Logette; Valérie Buchillier; Maude Muriset; Pierre Suchon; Thierry Daniel Pache; Goranka Tanackovic; Zoltán Kutalik; Joëlle Michaud
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

5.  ABO blood groups and risk of deep venous thromboembolism in Chinese Han population from Chaoshan region in South China.

Authors:  Min Yu; Cantian Wang; Tingting Chen; Shuang Hu; Kaihong Yi; Xuerui Tan
Journal:  Saudi Med J       Date:  2017-04       Impact factor: 1.484

6.  Combined Hormonal Contraceptives and First Venous Thrombosis in Young French Women: Impact of Thrombotic Family History.

Authors:  Justine Hugon-Rodin; Marie-Hélène Horellou; Jacqueline Conard; Anne Gompel; Geneviève Plu-Bureau
Journal:  J Endocr Soc       Date:  2017-04-20

7.  Hormonal therapies and venous thrombosis: Considerations for prevention and management.

Authors:  Corinne LaVasseur; Suvi Neukam; Thomas Kartika; Bethany Samuelson Bannow; Joseph Shatzel; Thomas G DeLoughery
Journal:  Res Pract Thromb Haemost       Date:  2022-08-23

Review 8.  Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk.

Authors:  Laure Morimont; Hélène Haguet; Jean-Michel Dogné; Ulysse Gaspard; Jonathan Douxfils
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-09       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.